Supinoxin Blocks Small Cell Lung Cancer Progression by Inhibiting Mitochondrial Respiration through DDX5
DDX5 is a DEAD-box RNA helicase that is overexpressed and implicated in the progression of several cancers, including small cell lung cancer (SCLC).  Our laboratory has demonstrated that DDX5 is essential for the invasive growth of SCLC and mitochondrial respiration.  SCLC is an extremely lethal, recalcitrant tumor, and currently lacking effective treatments. Supinoxin (RX 5902), a compound having anti-cancer activity, is a known target of phosphor-DDX5.  We now report that Supinoxin inhibits the proliferation of chemo-sensitive and chemo-resistant SCLC lines, H69 and H69AR respectively.  Additionally, Supinoxin mitigates both the growth of H69AR xenograft tumors and SCLC PDX tumors in vivo.    Finally, we find that Supinoxin inhibits expression of mitochondrial genes and effectively blocks respiration.  These studies suggest that Supinoxin functions in anti-tumor progression by reducing cellular energy levels through DDX5. Overall design: To investigate the molecular pathway through which Supinoxin works on SCLC, we conducted differential gene expression in H69AR chemoresistant SCLC cells with or without 70 nM of Supinoxin.